Allakos (ALLK) Downgraded by Zacks Investment Research to “Hold”

Share on StockTwits

Zacks Investment Research cut shares of Allakos (NASDAQ:ALLK) from a buy rating to a hold rating in a research report sent to investors on Friday morning.

According to Zacks, “Allakos Inc. is a clinical stage bio-technology company. It discovers and develops therapeutic antibodies for the treatment of allergic, inflammatory and proliferative diseases. Allakos Inc. is based in CA, United States. “

Shares of ALLK opened at $36.70 on Friday. Allakos has a fifty-two week low of $26.00 and a fifty-two week high of $65.48.

In other news, major shareholder Venture Fund (Ohi Rivervest II sold 52,837 shares of the stock in a transaction dated Thursday, January 24th. The shares were sold at an average price of $42.63, for a total transaction of $2,252,441.31. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director John P. Mckearn sold 142,219 shares of the stock in a transaction dated Tuesday, February 19th. The stock was sold at an average price of $34.49, for a total transaction of $4,905,133.31. The disclosure for this sale can be found here.

Several institutional investors and hedge funds have recently made changes to their positions in ALLK. Capital Research Global Investors acquired a new stake in shares of Allakos during the third quarter worth about $144,164,000. NEA Management Company LLC acquired a new stake in shares of Allakos during the third quarter worth about $102,046,000. FMR LLC acquired a new stake in shares of Allakos during the third quarter worth about $92,063,000. Redmile Group LLC acquired a new stake in shares of Allakos during the third quarter worth about $65,681,000. Finally, Capital International Investors acquired a new stake in shares of Allakos during the third quarter worth about $37,447,000. Institutional investors and hedge funds own 40.31% of the company’s stock.

About Allakos

Allakos Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis.

See Also: Municipal Bonds

Get a free copy of the Zacks research report on Allakos (ALLK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Allakos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allakos and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Allakos  Downgraded by Zacks Investment Research to “Hold”
Allakos Downgraded by Zacks Investment Research to “Hold”
ABIOMED  Upgraded to Hold by BidaskClub
ABIOMED Upgraded to Hold by BidaskClub
Consumer Edge Begins Coverage on Lamb Weston
Consumer Edge Begins Coverage on Lamb Weston
Nike  Stock Rating Reaffirmed by Credit Suisse Group
Nike Stock Rating Reaffirmed by Credit Suisse Group
Vermilion Energy  Cut to Hold at Zacks Investment Research
Vermilion Energy Cut to Hold at Zacks Investment Research
Smartsheet  Upgraded at Zacks Investment Research
Smartsheet Upgraded at Zacks Investment Research


© 2006-2019 Ticker Report